Mereo Research Development from 2010 to 2026

MREO Stock  USD 0.42  0  0.48%   
Mereo BioPharma Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to grow to about 35.9 M this year. During the period from 2010 to 2026, Mereo BioPharma Research Development quarterly data regression pattern had sample variance of 8618.9 T and median of  31,796,096. View All Fundamentals
 
Research Development  
First Reported
2016-03-31
Previous Quarter
5.4 M
Current Value
3.8 M
Quarterly Volatility
8.3 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Mereo BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mereo BioPharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 3.7 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 28.79, Dividend Yield of 0.0 or PTB Ratio of 8.02. Mereo financial statements analysis is a perfect complement when working with Mereo BioPharma Valuation or Volatility modules.
  
Build AI portfolio with Mereo Stock
Check out the analysis of Mereo BioPharma Correlation against competitors.
Evaluating Mereo BioPharma's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Mereo BioPharma Group's fundamental strength.

Latest Mereo BioPharma's Research Development Growth Pattern

Below is the plot of the Research Development of Mereo BioPharma Group over the last few years. It is Mereo BioPharma's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mereo BioPharma's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Mereo Research Development Regression Statistics

Arithmetic Mean92,644,825
Geometric Mean54,029,728
Coefficient Of Variation100.21
Mean Deviation85,947,226
Median31,796,096
Standard Deviation92,838,009
Sample Variance8618.9T
Range197M
R-Value(0.83)
Mean Square Error2836.8T
R-Squared0.69
Significance0.000035
Slope(15,287,289)
Total Sum of Squares137902.3T

Mereo Research Development History

202635.9 M
202518.8 M
202420.9 M
202317.4 M
202230.7 M
202131.8 M
202021 M

About Mereo BioPharma Financial Statements

Mereo BioPharma investors utilize fundamental indicators, such as Research Development, to predict how Mereo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development18.8 M35.9 M

Pair Trading with Mereo BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mereo Stock

  0.85DWTX Dogwood TherapeuticsPairCorr
  0.68EDIT Editas MedicinePairCorr

Moving against Mereo Stock

  0.7463E ONWARD MEDICAL BVPairCorr
  0.65IMMP Immutep Ltd ADRPairCorr
  0.54ENGN enGene Holdings CommonPairCorr
  0.5KYTX Kyverna TherapeuticsPairCorr
  0.42DSGN Design TherapeuticsPairCorr
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:
Check out the analysis of Mereo BioPharma Correlation against competitors.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Will Biotechnology sector continue expanding? Could Mereo diversify its offerings? Factors like these will boost the valuation of Mereo BioPharma. Expected growth trajectory for Mereo significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mereo BioPharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.25)
Revenue Per Share
0.003
Return On Assets
(0.40)
Return On Equity
(0.70)
Investors evaluate Mereo BioPharma Group using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mereo BioPharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mereo BioPharma's market price to deviate significantly from intrinsic value.
Understanding that Mereo BioPharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mereo BioPharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mereo BioPharma's market price signifies the transaction level at which participants voluntarily complete trades.